Navigating to Formulary Central
The information contained in this section of the site is intended for formulary decision makers only. Click "OK" if you are a formulary decision maker.
Duchenne Muscular Dystrophy Formulary Central
SPONSORED CONTENT
Clinical Impact of Disease Progression
An evidence-based event model for Duchenne muscular dystrophy in the United States
Characterizing the natural history of Duchenne muscular dystrophy in the United States in real-world commercial and medicaid data
The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review
The impact of genotype on outcomes in individuals with Duchenne muscular dystrophy: a systematic review
Economic Impact of Disease Progression
Disease progression stages and burden in patients with Duchenne muscular dystrophy using administrative claims supplemented by electronic medical records
Health-related quality of life and economic burden of Duchenne muscular dystrophy (DMD): a systematic literature review
Patient Quality of Life (QoL)
Factors associated with the health-related quality of life among people with Duchenne muscular dystrophy: a study using the Health Utilities Index (HUI)
The impact of key health state transitions on health-related quality of life in Duchenne muscular dystrophy: a qualitative study
Patient/Caregiver QoL
Characterizing the impact on work productivity in patients with DMD and caregivers: an economic analysis
Qualitative study to understand the Duchenne muscular dystrophy (DMD) experience from the caregiver/patient perspective
Societal Perspectives on QoL
QALYs and ambulatory status: societal preferences for healthcare decision making
Societal perspectives on disease and treatment attributes characterizing rare diseases: a qualitative study from the United States
Disease attributes most important from a societal perspective: a case study involving Duchenne muscular dystrophy
Societal perspectives on the importance of disease and treatment attributes: a qualitative study from the United States
Outcomes Assessments
The feasibility of using US claims data to assess outcomes in Duchenne muscular dystrophy
Value and Cost Assessments
Assessing the impact of single or short-term administration on a therapy's cost-effectiveness: a hypothetical disease-agnostic model
Commercial health plans use of patient subgroup restrictions: an analysis of orphan and US Food and Drug Administration-expedited programs
Determining the “severity premium” for Duchenne muscular dystrophy: a societal consideration for cost-effectiveness analysis
Manuscripts Permissions
This page is sponsored by Sarepta Therapeutics, Inc. For a complete citation list of articles posted on this page, please contact dbeadle@sarepta.com.
